Immuneering Corporation (IMRX)

Every figure this model derived for IMRX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2023-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 41,324,682 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 157,990,505 AssetsCurrent 2026-06-30
current liabilities 8,115,656 LiabilitiesCurrent 2026-06-30
equity 190,735,026 StockholdersEquity 2026-06-30
revenue 0 Revenues 2023-12-31
sbc 0 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up IMRX on one particular measure came for.

RatioValue
current ratio19.47
current ratio reported19.47
revenue growth-100.0
revenue growth per share-100.0

What to be careful about

What this model itself distrusts about IMRX's figures. Written by the derivation as it ran, not added afterwards.